R&D innovative technologiesin the pharmaceutical sector and the challenges in their implementation in the EU

The pharmaceutical industry is constantly changing, and patients necessities waiting for treatment are numerous. New diseases and those that do not have treatment are constant factors demanding the pharmaceutical industry look at recent trends in R&D, search for different scientific solutions, and focus on innovation. It is essential to know the R&D innovative technologies, applications, and development in the current landscape, driving the pharmaceutical sector forward. In the new context, where the European Union has 27 countries, the European Medicines Agency (EMA) regulates approvals and population worldwide lives in the context of the Covid-19 pandemic. The vision of opting for new technology, knowing the trends in R&D, science, and innovation opens a panorama of opportunities and challenges for the pharmaceutical sector. The study comprises qualitative and quantitative approaches to investigated innovative technologies and their challenges in pharmaceutical R&D. Data generation have been carried out with scientists working in R&D, pharmaceutical professionals, and regulatory professionals, followed by an analysis of information available through documentary research. Findings have shown that the most challenging factor influencing the R&D innovative technology approval is regulatory standardization. This factor has led to the major constraint in implementing innovative technologies, while Technology cost has been identified as the second challenging constraint. R&D innovative technologies represent an advantage in a COVID-19 pandemic context through gene therapies and digital transformation with access to big data in real-time. R&D management performs a principal role in the implementation of new technology. As Claud-based data management has been the main Pharma 4.0 element implemented in the EU in recent years, Policy and regulatory activity and Data integrity and cybersecurity will represent the pharmaceutical sector's major challenges in the next ten years